home · filing · 0001516551-23-000071
8-K/A filed September 1, 2023, 7:59 PM ET
ticker SKYE
CIK 0001516551
leadership
confidence high
sentiment neutral
materiality 0.60
Skye Bioscience appoints Schwab and Grayson to board; Grayson gets $350k bonus and large performance RSUs
Skye Bioscience, Inc.
Paul Grayson appointed director with a $350,000 sign-on bonus.
18.1M performance RSUs vest on market cap milestones: $125M, $250M, $400M, or $500M+ exit.
Additional 43.4M performance RSUs subject to stockholder approval of plan amendment.
Andrew Schwab appointed to board and compensation committee; standard non-employee director compensation.
7.4M stock options granted to non-employee directors; up to 17.6M more pending plan amendment.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Andrew Schwab
Director
SKYE ·
Skye Bioscience, Inc.
Filed September 1, 2023, 7:59 PM ET
Andrew Schwab and Paul Grayson were appointed to the Board.
Appointed
Paul Grayson
Director
SKYE ·
Skye Bioscience, Inc.
Filed September 1, 2023, 7:59 PM ET
Andrew Schwab and Paul Grayson were appointed to the Board.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Andrew Schwab was appointed as Director at Skye Bioscience, Inc..
Action appointed
Role Director
Exact text from the filing
Andrew Schwab and Paul Grayson were appointed to the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul Grayson was appointed as Director at Skye Bioscience, Inc..
Action appointed
Role Director
Exact text from the filing
Andrew Schwab and Paul Grayson were appointed to the Board.
View on SEC.gov
Source: SEC EDGAR
accession 0001516551-23-000071
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.